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Introduction
The hesitation on the part of many in the interventional 
pulmonology community to perform percutaneous pleural 
drainage in patients receiving clopidogrel is an extrapolation 
of traditional surgical concerns about operating on patients 
in the setting of profound platelet inhibition. When it comes 
to hemostasis, the surgeon’s situation is both comparatively 
advantageous and disadvantageous. On the one hand, 
surgery is a more radical intervention than a percutaneous 
procedure with the possibility of major vascular injury. 
On the other hand, the surgeon has better access to the 
site of iatrogenic bleeding and has the technical ability to 
achieve hemostasis by means of immediate operative repair. 
Solving this problem by suspending clopidogrel therapy 
constitutes a potentially significant safety compromise, 
especially in patients who have undergone recent coronary 
stenting. Moreover, pleural drainage is often urgent 
enough to preclude the possibility of delaying it until 
the effect of clopidogrel dissipates. In the current era of 
routine ultrasound (US) guidance and shift to smaller 
tubes, the possibility that percutaneous pleural drainage 
can be performed safely while continuing clopidogrel is 
being raised increasingly in interventional pulmonology 
circles (1). In this review, we familiarize the reader with 
the pharmacology of clopidogrel, review the risks posed 
by its periprocedural discontinuation, discuss potentially 
applicable data from the thoracic surgery and interventional 
radiology literature, and summarize the available studies of 
percutaneous pleural drainage in those taking clopidogrel. 
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Finally, we attempt to draw conclusions for clinical practice 
based on the totality of current evidence. 
Background of thienopyridines
Platelet plugs serve as the initial mechanism of hemostatic 
repair of vascular endothelial injury and are eventually 
reinforced by a fibrin mesh to form a mature clot. For 
therapeutic inhibition of clotting, platelet receptors 
regulating activation and aggregation, such as the 
adenosine diphosphate (ADP) receptor P2Y12, have long 
been attractive targets (2). The thienopyridines were the 
first class of medications developed to antagonize the 
ADP P2Y12 receptor. Members of this drug class, which 
includes ticlopidine, clopidogrel, and prasugrel, exert 
their antiplatelet effect by irreversibly blocking the P2Y12 
receptor from interacting with its ligand ADP (3). This 
interrupts the cascade of platelet activation and aggregation 
that ultimately leads to clot formation (3-6). The inhibitory 
effect of these medications lasts for the lifetime of the 
platelet (7). 
All thienopyridines are oral prodrugs that require 
conversion to active metabolites (3,8). Ticlopidine and 
clopidogrel require two conversion steps to generate their 
active metabolites, which results in a delayed onset of 
action (9,10). Once cumulative dosing reaches a therapeutic 
level, however, recovery of platelet function after drug 
withdrawal occurs slowly (3,11). Prasugrel has a more rapid 
onset of action and requires only one step to generate 
its active metabolites (3). The clinical use of the first-
generation agent ticlopidine has been limited by bone 
marrow toxicity (12). Third-generation prasugrel has the 
most potent inhibitory effect, but this advantage is offset by 
its tendency to increase bleeding events (13-15). As a result, 
clopidogrel—the second-generation thienopyridine—
remains the most widely used option in this drug class. It 
suffers from great variability of the antiplatelet response 
due in part to different rates of absorption and to 
polymorphisms of the regulatory gene CYP2C19 involved 
in the generation of its active metabolites (3,13,16). 
Clopidogrel has a half-life of approximately 8 hours with 
platelet inhibition starting at 48 hours with daily oral dosing 
of 50–100mg. Steady state levels are reached after 4–7 days, 
and the antiplatelet effect lingers for 7–10 days (17,18). 
Figure 1 Graphical representation of the mechanism of action of the clinically important thienopyridines, clopidogrel and prasugrel, 
as well as of other antiplatelet agents. Of note, although it is also an antagonist of the P2Y12 receptor, ticagrelor does not belong to the 
thienopyridine family. AA, arachidonic acid; COX-1, cyclooxygenase-1; CP450, cytochrome P450; P2Y12, purinergic receptor P2Y; 
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Despite these shortcomings, clopidogrel is well-established 
therapy for patients with cerebrovascular disease, peripheral 
vascular disease, acute coronary syndromes, and for those 
undergoing percutaneous coronary intervention (PCI), 
particularly with stent placement (14,19-24). Figure 1 
graphically illustrates the mechanism of action of the 
thienopyridines as well as other commonly used antiplatelet 
agents.
Cardiac risks of clopidogrel discontinuation
Patients with recently placed coronary stents on APT that 
includes clopidogrel pose a clinical dilemma if non-cardiac 
surgery is required. On one side are fears about increased 
bleeding risk and failure of intraoperative hemostasis. On 
the other is this population’s predisposition to adverse 
perioperative cardiac events if APT is discontinued 
prematurely (26,27). In patients with coronary stents, 
premature discontinuation of clopidogrel is associated with 
an increased risk for thrombosis (13,28,29), myocardial 
infarction (30), and an increase in overall mortality 
(29,31,32). This is particularly true for those receiving 
drug-eluting stents (DES) because several studies have 
reported a 29% or greater increase in the risk of coronary 
thrombosis if clopidogrel is withdrawn prematurely 
(17,29,33). In a prospective multi-center, observational 
cohort of 1,134 patients with coronary stents, the strongest 
independent risk factor for stent thrombosis within 
30 days of PCI was the absence of clopidogrel therapy. 
There was also a strong association with stent thrombosis 
if clopidogrel was discontinued between 30 days and 
6 months, and even beyond 6 months of the index PCI (34). 
A systematic review and meta-analysis found that after the 
recommended minimum 12-month period of dual APT for 
DES, there is still an increased risk for death and coronary 
events associated with stopping these medications (35). Data 
suggest that the most significant independent risk factor 
for perioperative coronary stent thrombosis and myocardial 
infarction is the discontinuation of oral APT for more than 
5 days prior to non-cardiac surgery (13,36,37).
Thoracic surgery and clopidogrel
Historically, thoracic surgeons have been reluctant to 
operate in the chest of patients obligated to take clopidogrel 
for recent cardiac stenting. This poses a problem when the 
surgery is urgent, such as in the case of empyema, and even 
when it is time-sensitive, such as resection of lung cancer. 
Cerfolio et al. were the first to publish their experience of 
performing thoracic surgery without interruption of APT, 
which could have been clopidogrel alone or clopidogrel 
plus aspirin (17). None of the 27 patients whom they took 
to the operating room (OR) on APT for primary surgery 
required blood transfusions or re-operation for bleeding. 
However, both patients taking aspirin and clopidogrel who 
were undergoing repeat thoracic surgery required a return 
to the OR for bleeding. Additionally, the patients receiving 
APT at the time of surgery had a significantly greater chest 
tube output during the first 2 post-operative days. Of note, 
this series did not include any operations in the pleural 
space. Ceppa et al. subsequently analyzed 54 patients who 
underwent mostly thoracoscopic lung cancer resection 
during treatment with clopidogrel and compared them to 
108 historical, propensity score matched controls not treated 
with clopidogrel perioperatively (38). Only one patient, 
from the control group, required reoperation for bleeding. 
There was no difference between the groups in the need 
for blood transfusion or prolonged chest tube drainage. 
Yu et al. reported a series of 58 patients who underwent 
lung resectional surgery on APT; half were taking 
clopidogrel (n=18) or clopidogrel plus aspirin (n=11) (39). 
Three patients experienced post-operative bleeding, all were 
recipients of dual therapy, but none required re-operation. 
Four of the 11 dual therapy patients received blood 
transfusions postoperatively, and all four had extensive 
pleural adhesions encountered at surgery. The dual therapy 
patients had significantly greater chest tube output than 
those receiving other forms of APT. Within the limitations 
of available data, initial resectional thoracic surgery on APT 
appears to be safe, with the caveat that operations on dual 
therapy that require extensive lysis of pleural adhesions 
may be associated with bleeding complications. However, 
there is no existing evidence on the safety of primary 
pleural surgery in patients receiving clopidogrel alone or in 
combination.
Interventional radiology procedures and 
clopidogrel
There are limited data on the safety of percutaneous 
procedures performed under radiological guidance in 
persons taking clopidogrel. While recommendations from 
the OR may be extrapolated to image-guided percutaneous 
procedures, the inability of the interventionalist to directly 
visualize and promptly control bleeding presents a unique 
risk (40). In 2012, the Society of Interventional Radiology 
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(SIR) published consensus guidelines for periprocedural 
antiplatelet management according to the bleeding risk 
of each percutaneous image-guided intervention. All 
recommendations were based on the assumption of an 
elective interventional procedure and of a single hemostatic 
defect (41).
Procedures labeled as category 1 are considered to have 
a low-risk of bleeding, which would be easily detected 
and managed. These include drainage catheter exchange, 
thoracentesis, paracentesis, superficial abscess drainage, 
joint aspiration and injection, and superficial aspiration or 
biopsy. The recommendation is to withhold clopidogrel 
for 0–5 days prior to such interventions and to continue 
aspirin therapy. Category 2 procedures are associated with 
a moderate risk of bleeding, and the recommendation is 
to continue aspirin and hold clopidogrel for 5 days. This 
category includes biopsies of the chest wall and lung as well 
as intra-abdominal and retroperitoneal abscess drainage or 
biopsy. Category 3 procedures, such as renal biopsy, pose 
the highest risk of bleeding, which would be difficult to 
identify and control. Both aspirin and clopidogrel should be 
held for 5 days prior to these procedures according to the 
SIR guidelines.
In the years since the SIR guidelines were issued, only 
two studies directly addressing APT management for 
percutaneous interventions by interventional radiologists 
have been published. One large retrospective study of 
image-guided percutaneous deep core needle biopsies 
found the overall incidence of major bleeding events to 
be low (0.5%) (42). In the subset of 246 patients who 
were taking clopidogrel in proximity to the procedure, 
there was only one major bleeding event (0.41%), which 
occurred in a patient within 7 days of clopidogrel ingestion. 
Limitations of this study include inconsistent data about 
the timing of last clopidogrel exposure and about aspirin 
co-administration. More informative is a recent study by 
Pieper et al. of 63 patients who had undergone various 
image-guided core needle biopsies. All subjects took 
clopidogrel within 5 days of the procedure with a mean 
abstinence time of 2.9 days prior to needle insertion. Twelve 
procedures were performed within 24 hours of clopidogrel 
ingestion. There were 48 patients (76%) who also took 
aspirin within 5 days of the procedure (43). There was only 
one significant iatrogenic bleeding event (1/63; 1.6%), 
which occurred after laceration of an intercostal artery 
during CT-guided pulmonary nodule biopsy. 
Aggregating the encouraging, albeit limited, safety 
data on performing category 2 and 3 percutaneous needle 
procedures and even certain types of thoracic surgery 
in patients receiving clopidogrel, one might reasonably 
conclude that category 1 procedures, such as thoracentesis, 
should fare as well as, if not better than, these higher risk 
interventions. However, there is a paucity of direct evidence 
confirming the safety of clopidogrel use in category 
1 percutaneous needle procedures. Fortunately, whatever 
data do exist come predominantly from studies of 
thoracentesis and chest tube insertion.
Percutaneous pleural procedures and 
clopidogrel
As mentioned, thoracentesis is categorized as a low-risk 
procedure for bleeding according to expert opinion and 
guidelines (40,44). The bleeding concern relates primarily 
to iatrogenic hemothorax from injury of the intercostal 
artery, and less so bleeding from damage to a viscus, such 
as might occur if the spleen is inadvertently punctured. US 
guidance improves procedural accuracy in thoracentesis, 
so sub-diaphragmatic entry should be less of a concern 
in the US era (45). The ability of color Doppler US to 
identify intercostal vessels when selecting the safest site for 
thoracentesis has been demonstrated, but this step has not 
been universally adopted in clinical practice (46). When 
performed by experienced operators with standard US 
guidance, the overall hemothorax rate is exceedingly low. 
In their published experience with over 9,300 thoracentesis 
procedures, Ault et al. recorded only 5 hemothoraces, a 
rate of 0.05% (47). When large data sets from the Mayo 
Clinic were retrospectively analyzed, there were no 
hemothoraces even in patients who underwent thoracentesis 
with abnormal coagulation parameters, which casts doubt 
on the need for routine laboratory studies prior to this 
procedure (48,49). Likewise, no hemothoraces occurred 
in 60 patients with thrombocytopenia (<50 K/µL) or 
coagulopathy [international normalized ratio (INR) >1.5] 
subjected to thoracentesis as part of a prospective 
observational cohort at Yale-New Haven Hospital (50).
A separate body of literature exists on the safety 
of performing pleural drainage in patients receiving 
clopidogrel. For study purposes, thoracentesis and small-
bore (i.e., ≤14 French) chest tube placement are considered 
to be analogous. This is a reasonable assumption because 
small-bore chest tubes placed using the Seldinger 
technique have a comparably favorable safety profile to 
that of thoracentesis (51,52). In fact, in some institutions, 
therapeutic thoracentesis may consist of the temporary 
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insertion of a very small (e.g., eight French) pigtail catheter 
into the pleural space, in which case the two procedures 
are essentially indistinguishable. There are some practical 
differences, however, between the two procedures in the 
event of a hemothorax caused by the procedure itself. One 
is that an iatrogenic hemothorax should be apparent more 
quickly when the drainage catheter is left in place based on 
the appearance of the output. Another is that the placement 
of a drain is in itself the first step in the management of 
an iatrogenic hemothorax until it is determined whether a 
hemostatic intervention is required.
The retrospective data on pleural drainage and 
clopidogrel encompass a total of 54 patients across two 
studies who underwent 67 US-guided small-bore chest 
tube insertions (53,54). No life-threatening bleeding 
was reported in any of these procedures. In the earliest 
prospective study, Zalt et al. performed 45 US-guided 
thoracentesis procedures in 30 patients on clopidogrel, 
and in their sample there was 1 instance of a superficial 
hematoma at the puncture site that did not lead to a 
significant drop in hemoglobin (36). Mahmood et al. 
prospectively enrolled 25 consecutive subjects who 
underwent thoracentesis or small-bore chest tube placement 
while taking clopidogrel and compared this group to 
50 contemporaneous patients who likewise underwent 
pleural drainage but without clopidogrel (55). There 
was one hemothorax during the study, which occurred 
in the clopidogrel cohort, as indicated by a 1.6 gm/dL 
decrease in hemoglobin post-procedure in conjunction 
with increased pleural effusion on chest X-ray. The 
hemothorax was managed successfully with small-bore chest 
tube placement. Puchalski et al. conducted a prospective 
study of 312 thoracentesis patients, 130 of whom had an 
increased bleeding risk as defined by the investigators (50). 
Eighteen of the 130 patients (14%) assigned to the increased 
risk group were being actively treated with clopidogrel; 
8 of these 18 also had other predispositions to bleeding. 
No hemothoraces occurred in the entire study, and the 
change in hematocrit post procedure was not significantly 
different between those with and without a bleeding risk. 
Taken together, these small studies report one instance of 
hemothorax in a sample of 155 pleural procedures. This 
translates to a bleeding rate of 0.6%, which is still higher 
than that in the study by Ault et al. quoted above in a general 
population undergoing thoracentesis but is comparable to, 
for example, conventional transbronchial biopsy in persons 
not taking antiplatelet agents and is certainly lower than 
that reported for bronchoscopic cryobiopsy (56,57). Table 1 
summarizes and aggregates the bleeding rates reported by 
the aforementioned studies.
Conclusions
At the present time, only observational data are available to 
Table 1 Summary of five available studies reporting bleeding rates associated with pleural drainage on clopidogrel
Authors Study type Procedure(s) 
Number of 
procedures 







Dammert et al., 
2013 (54)
Retrospective Chest tubea 43a 91% None 43 0
Abouzgheib  
et al., 2012 (53)
Retrospective Chest tubeb 24b 72% None 24 0
Mahmood  
et al., 2014 (55)
Prospective Chest tube and 
thoracentesis
25c 88% 1/25; 4%d 8 17
Zalt et al.,  
2012 (36)
Prospective Thoracentesis 45e Not reported None 0 45
Puchalski et al., 
2013 (50)
Prospective Thoracentesis 18f Not reported None 0 18
Total – – 155 – 1 75 80
Major bleeding – – – – 1/155; 0.6% 0 1/80; 1.25%
a, 43 procedures in 30 patients: 8 Fr =11, 14 Fr =27, 16 Fr =5; b, 24 procedures in 18 patients: 8 Fr =9, 10 Fr =1, 12 Fr =3, 14 Fr =1, 16 Fr 
=10; c, 25 procedures in 25 patients: 17 thoracenteses and 8 chest tubes (all 14 Fr); d, 1 patient with hemothorax after thoracentesis while 
on clopidogrel and aspirin; e, 45 procedures in 30 patients; f, 18 procedures in 18 patients. 
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guide conclusions about the safety of percutaneous pleural 
drainage in patients taking clopidogrel. In aggregate, the 
evidence allows one to conclude that urgent percutaneous 
pleural drainage using current techniques can be performed 
with an acceptable safety profile in patients treated with 
clopidogrel. Of course, if deemed feasible, a lower bleeding 
risk would be achieved if the drainage were delayed for at 
least 5 days while the clopidogrel is withheld. Concordant 
results of larger, collaborative, ideally prospective 
randomized studies, or at least big registry data, are needed 
to strengthen the level of confidence in such an approach to 
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